Józefczuk Paweł, Biliński Jarosław, Minkowska Aleksandra, Łaguna Paweł
Department of Oncology, Pediatric Hematology, Clinical Transplantology and Pediatrics, Medical University of Warsaw, Poland.
Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland; Human Biome Institute, Gdansk, Warsaw, Poland.
Best Pract Res Clin Gastroenterol. 2024 Sep;72:101955. doi: 10.1016/j.bpg.2024.101955. Epub 2024 Oct 24.
Hematopoietic stem cell transplantation (HSCT) is used in children as a treatment for various cancers, e.g. acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or other diseases, e.g. severe congenital immunodeficiency, metabolic disorders, hence the patient population is quite diverse. There is an increasing interest on the role of the microbiome in peri-transplant period. In this review, concepts of HSCT with the focus on the importance of microbiome composition, its changes during treatment and possible microbiota oriented interventions will be discussed. This paper analyzes data in pediatric population, but in view of interesting results and absence of analogous data for pediatric patients, it also looks at studies performed on adult population and pre-clinical trials on animals discussing possible translation to children.
造血干细胞移植（HSCT）在儿童中用于治疗各种癌症，例如急性淋巴细胞白血病（ALL）、急性髓系白血病（AML），或其他疾病，例如严重先天性免疫缺陷、代谢紊乱，因此患者群体相当多样化。人们对微生物群在移植期间的作用越来越感兴趣。在这篇综述中，将讨论以微生物群组成的重要性、其在治疗期间的变化以及可能的以微生物群为导向的干预措施为重点的HSCT概念。本文分析了儿科人群的数据，但鉴于有趣的结果以及缺乏儿科患者的类似数据，它也研究了在成人人群中进行的研究以及在动物身上进行的临床前试验，讨论了向儿童转化的可能性。
